RxDoctor Payments Data

Edwin Matthews, MD

Family Medicine · Decatur, ALNPI 1316965908

Payments from drug & device makers

$14,366in general payments, 2019–2025

Across 1,002 payments — averaging $14.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Amarin Pharma, Inc.$1K
  • Lilly USA, LLC$1K
  • GSK$838
  • plus $6K from 42 others

What the payments were for

  • Food & beverage$14,27099%
  • Education$961%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,366 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$91,277
Medicare patients
228
Services billed
1,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban107$97,670
OzempicSemaglutide55$79,889
MounjaroTirzepatide58$77,045
JardianceEmpagliflozin78$76,506
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$75,621
JanuviaSitagliptin Phosphate49$64,142
FarxigaDapagliflozin Propanediol59$48,951
XareltoRivaroxaban34$25,652
TrulicityDulaglutide13$22,388
LinzessLinaclotide17$17,244
MyrbetriqMirabegron15$13,969
Tresiba Flextouch U-100Insulin Degludec20$13,467
Janumet XrSitagliptin Phos/Metformin Hcl17$13,359
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide163$12,179
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog22$11,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid, Premarin$634$110,076142 claims
Lilly USA, LLCMounjaro, Trulicity$1,043$99,43471 claims
Novo NordiskOzempic$2,349$79,88955 claims
MerckJanuvia, Janumet Xr$249$77,50166 claims
Boehringer IngelheimJardiance$453$76,50678 claims
GSKTrelegy Ellipta$838$75,62166 claims
AstraZenecaFarxiga$1,314$48,95159 claims
Johnson & JohnsonXarelto$273$25,65234 claims
AbbVieLinzess$1,416$17,24417 claims
Astellas Pharma US IncMyrbetriq$232$13,96915 claims
NovartisEntresto$183$7,00911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Decatur

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →